Solitary solutions to an androgen-deprivation prostate cancer treatment model

被引：3

作者：

Telksnys, T. ^{[1
]}

Timofejeva, I. ^{[1
]}

Navickas, Z. ^{[1
]}

Marcinkevicius, R. ^{[2
]}

Mickevicius, R. ^{[3
]}

Ragulskis, M. ^{[1
]}

机构：

[1] Kaunas Univ Technol, Ctr Nonlinear Syst, Studentu 50-147, LT-51368 Kaunas, Lithuania

[2] Kaunas Univ Technol, Dept Software Engn, Studentu 50-415, LT-51368 Kaunas, Lithuania

[3] Lithuanian Univ Hlth Sci, Urol Clin, Eiveniu 2, LT-50009 Kaunas, Lithuania

来源：

MATHEMATICAL METHODS IN THE APPLIED SCIENCES | 2020年 / 43卷 / 07期

关键词：

androgen deprivation therapy; prostate cancer model; solitary solution; IDENTIFICATION; SYSTEMS;

D O I：

10.1002/mma.6168

中图分类号：

O29 [应用数学];

学科分类号：

070104 ;

摘要：

A model of androgen deprivation treatment for prostate cancer is considered in this paper. Bright/dark solitary solutions to the model are constructed using inverse balancing and generalized differential operator techniques. It is shown that solitary solutions correspond to biomedically relevant sets of model parameters. Dynamical properties of solitary solutions are analyzed in the phase plane. It is demonstrated that such solutions closely reflect the real-world phenomena observed during androgen deprivation treatment. Computational experiments are used to illustrate these effects.

引用

页码：3995 / 4006

页数：12

共 50 条

[41] Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer
Potosky, Arnold L.
Haque, Reina
Cassidy-Bushrow, Andrea E.
Yood, Marianne Ulcickas
Jiang, Miao
Tsai, Huei-Ting
Luta, George
Keating, Nancy L.
Smith, Matthew R.
Van Den Eeden, Stephen K.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1324 - +
[42] COMPLICATIONS OF ANDROGEN-DEPRIVATION THERAPY IN PROSTATE CANCER: THE OTHER SIDE OF THE COIN
Hoffmann, Paul
Schulman, Claude
BJU INTERNATIONAL, 2009, 103 (08) : 1020 - 1023
[43] New guidelines for androgen-deprivation therapy treatment of non-metastatic prostate cancer developed
不详
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2011, 6 (03) : 324 - 324
[44] Androgen deprivation treatment in prostate cancer
Thomas, Benjamin C.
Neal, David E.
BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
[45] Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment
Inaba, M
Otani, Y
Nishimura, K
Takaha, N
Okuyama, A
Koga, M
Azuma, J
Kawase, I
Kasayama, S
METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (01): : 55 - 59
[46] Adjuvant Androgen-Deprivation Therapy for Prostate Cancer Should Docetaxel Be Added?
Vogelzang, Nicholas J.
JAMA ONCOLOGY, 2019, 5 (05) : 633 - 634
[47] A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients
C Jin
Y Fan
Y Meng
C Shen
Y Wang
S Hu
C Cui
T Xu
W Yu
J Jin
Prostate Cancer and Prostatic Diseases, 2016, 19 : 333 - 339
[48] Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
Ross, Robert W.
Oh, William K.
Xie, Wanling
Pomerantz, Mark
Nakabayashi, Mari
Sartor, Oliver
Taplin, Mary-Ellen
Regan, Meredith M.
Kantoff, Philip W.
Freedman, Matthew
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 842 - 847
[49] Androgen-Deprivation Therapy for Prostate Cancer and Rise in HbA1C
DeCarlo, K. E.
Blachman, N. L.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S91 - S91
[50] Review of Major Adverse Effects of Androgen-deprivation Therapy in Men With Prostate Cancer
Taylor, Lockwood G.
Canfield, Steven E.
Du, Xianglin L.
CANCER, 2009, 115 (11) : 2388 - 2399

← 1 2 3 4 5 →